Ultragenyx (RARE) Crashes 47% on GTX-102 Failure

Ultragenyx RARE fell 47% after GTX-102 missed every primary and secondary endpoint in the ASPIRE Phase 3 Angelman syndrome study, triggering mass downgrades.

RARE shares collapsed 46.93% to approximately $14.50 on September 3, wiping out more than $1.2 billion in market capitalization in a single session.
The Phase 3 ASPIRE trial produced zero efficacy differences between treated and control groups across all five MDRI sub-domains, leaving no statistical basis for a partial approval claim.
At least six brokerages downgraded the stock, with price targets slashed 53% to 64%, as the company announced a 10% workforce reduction and a full strategic review.

Lead

Ultragenyx Pharmaceutical (RARE) suffered one of the most severe single-session wipeouts in the biotech sector in 2026 after the Phase 3 ASPIRE study of apazunersen (GTX-102), its antisense oligonucleotide therapy for Angelman syndrome, missed every primary and key secondary endpoint. Shares closed September 3 at approximately $14.50, down 46.93% from a prior close of $26.53, as the company simultaneously announced a restructuring program, a workforce reduction, and a formal review of the drug's future - eliminating what had been its most closely watched pipeline asset.

What Did the ASPIRE Trial Show?

The ASPIRE study enrolled approximately 129 patients aged four to 17 with genetically confirmed full maternal UBE3A gene deletion - the most common genetic subtype of Angelman syndrome - and found no improvement on the Bayley-4 cognitive raw score, the primary endpoint, compared with controls. The key secondary endpoint, the Multi-domain Responder Index (MDRI), was also missed across all five constituent sub-domains: cognition, receptive communication, behavior, gross motor function, and sleep. No efficacy signal appeared in any domain. The drug's safety profile was consistent with Phase 1/2 data, ruling out toxicity as a confounding variable and pointing instead to a fundamental failure of the therapeutic mechanism to generate clinical benefit in this population.

Jefferies described the outcome as "a clear signal failure and not a design failure," closing off the possibility of trial redesign or endpoint renegotiation as a path forward.

Why Did Investors React This Severely?

Apazunersen had carried FDA Breakthrough Therapy Designation and represented the most commercially significant item in Ultragenyx's pipeline. Angelman syndrome has no approved treatments, giving GTX-102 an open market and significant pricing power if it had succeeded. The total absence of a signal across every domain left no subgroup data for a rescue strategy and no clinical foothold for regulators - removing a catalyst that Wall Street had priced as a near-term binary event.

The failure also cast doubt on the related AURORA study, which is evaluating GTX-102 across additional Angelman genotypes and age groups. William Blair noted that even a positive AURORA result would face commercial challenges given the limited addressable patient population, a comment that pulled forward skepticism on the entire GTX-102 franchise in one announcement.

Analyst Reaction and Downgrades

At least six major brokerages moved to neutral or equivalent ratings within hours:

William Blair cut to Market Perform from Outperform, citing AURORA uncertainty and limited near-term catalysts.
Evercore ISI dropped to In Line from Outperform, cutting its price target from $34 to $16.
Baird downgraded to Neutral from Outperform, slashing its target from $40 to $16.
RBC Capital Markets moved to Sector Perform from Outperform with a $19 target.
Wells Fargo cut to Equal Weight from Overweight, reducing its target from $50 to $18.
JPMorgan downgraded to Neutral from Overweight, lowering its target from $80 to $36.

Price-target reductions ranged from 53% to 64%, reflecting a repricing of the entire growth thesis rather than a single-asset write-down.

What Happens Next for Ultragenyx?

Management announced a 10% workforce reduction affecting approximately 130 employees alongside operating expense cuts targeting at least 15% below 2025 levels. The company said it will evaluate "the disposition" of the GTX-102 program - language consistent with potential out-licensing or discontinuation. Resources are being redirected toward two remaining pipeline candidates: DTX-401 for glycogen storage disease type 1a and UX-111 for Sanfilippo syndrome type A.

Ultragenyx reaffirmed 2026 total revenue guidance of $730 million to $760 million and maintained its trajectory toward profitability in 2027, anchored by its existing approved rare-disease portfolio rather than any GTX-102 proceeds.

Outlook

The ASPIRE failure forces Ultragenyx into a pivot from a high-risk, high-reward pipeline story to a leaner commercial rare-disease model. The AURORA study remains the next significant data readout for the GTX-102 program, but with investor expectations now sharply reduced. For the broader biotech sector, the result adds to a growing record of caution around antisense oligonucleotide therapies targeting gene expression in pediatric neurological rare diseases - a category where mechanistic promise has repeatedly outpaced clinical translation.

Mentioned tickers: RARE